Prescriptions by GPs in Wales, 2016-17

Prescription statistics published here are based on information obtained from prescriptions sent for payment to Prescribing Services, NHS Wales Shared Services Partnership.

The data is presented largely in terms of 'prescription items' which refers to single items prescribed by a doctor on a prescription form. If a prescription form includes three items it is counted as three prescription items. Full definitions are included in the notes section at the end of the release.

A large amount of complex data on prescriptions is available; it should be interpreted with the explanatory notes provided at the end of the release and with reference to the Quality Report.

Data captured by Prescribing Services in the prescription pricing and remuneration process are also available on their website.

Chart 1: Prescription items, since 1973

- The number of items prescribed in Wales in 2016-17 was 80.0 million - up from 21.3 million in 1973 (275%), and from 59.1 million in 2006-07 (35%).
- The increase in items prescribed between 2015-16 and 2016-17 was 1.1%, slightly up on the 0.8% increase in the previous year.
- The number of items per head (registered with a GP) in 2016-17 was 25.0 – up from 7.6 in 1973 (229%), and from 19.1 in 2006-07 (31%).
- Items per head rose by 1.1% over the year.

Source: NHS Wales Shared Services Partnership

(a) see notes for further details

About this release

This release gives information on items which were prescribed by GPs in Wales, and dispensed, during the year. These are referred to in the release as items ‘prescribed’ by GPs. Items prescribed but not dispensed are excluded.

The release also highlights the main trends and patterns in prescribing over previous years, and aims to provide statistical context for current prescribing policy in Wales.

Further data can be found on StatsWales, our interactive data dissemination service.

In this release

- Prescribing trends 3
- Therapeutic classes 2016-17 4
- Therapeutic classes 10 year trend 6
- Analysis by LHBs 10
- Key Quality Information 13
- Notes 17
Contents

Chart 1: Prescription items, since 1973 ................................................................. 1
Prescribing trends .................................................................................................. 3
Chart 2: Net ingredient cost, 2000-01 onwards ..................................................... 3
Chart 3: Items prescribed generically (%), 2000-01 onwards ............................... 3
Therapeutic Classes – 2016-17 ........................................................................... 4
Chart 4: Items by therapeutic class, 2016-17 ....................................................... 4
Chart 5: NIC by therapeutic class, 2016-17 ......................................................... 4
Chart 6: Net ingredient cost per item, by therapeutic class 2016-17 ..................... 5
Therapeutic Classes - 10 year trend ..................................................................... 6
Chart 7: Prescription items by top ten therapeutic classes in 2016-17 compared with 2006-07 .......... 6
Chart 8: Net ingredient cost by top ten therapeutic classes in 2016-17 compared with 2006-07 .......... 7
Chart 9: Net ingredient cost per prescription item by top ten therapeutic classes in 2016-17 compared with 2006-07 .......... 8
Chart 10: Items and net ingredient cost, annual percentage change, 2006-07 to 2016-17 .......... 9
Charts 11a to c: Annual percentage change of the number of items dispensed in the three largest classes (cardiovascular, central nervous and endocrine systems) ............. 9
Analysis by Local Health Board ......................................................................... 10
Chart 12: Number of prescription items per prescribing unit, by Local Health Board, 2016-17 .......... 10
Chart 13: Net ingredient cost per prescribing unit, by Local Health Board, 2016-17 .......... 10
Chart 14a: Number of items per prescribing unit, cardiovascular system, 2016-17 .......... 11
Chart 14b: Number of items per prescribing unit, central nervous system, 2016-17 .......... 11
Chart 14c: Number of items per prescribing unit, endocrine system, 2016-17 .......... 12
Chart 14d: Number of items per prescribing unit, gastro-intestinal system, 2016-17 .......... 12
Chart 14e: Number of items per prescribing unit, respiratory system, 2016-17 .......... 12
Key Quality Information ...................................................................................... 13
Definitions: .......................................................................................................... 13
Therapeutic Class: .............................................................................................. 16
Notes: .................................................................................................................. 17
Prescribing trends

Chart 2 shows the net ingredient cost (NIC) - see note (a) - of items prescribed by GPs in Wales, and the NIC per head of population registered with a GP.

Chart 2: Net ingredient cost, 2000-01 onwards

The net ingredient cost of items prescribed by GPs in Wales in 2016-17 was £577 million, up from £411 million in 2000-01 (40%) but down from £579 million in 2006-07 (0.4%).

The NIC per head of population registered with a GP increased from £136.51 in 2000-01 to £189.73 (the highest) in 2004-05, but fell to £180.34 in 2016-17.

Note: NIC per head (£) NIC (£ millions)

Source: NHS Wales Shared Services Partnership

Free prescriptions introduced in Wales on 1 April 2007

(a) Refers to the cost (which the dispenser is reimbursed) of the drug before discounts and does not include any dispensing costs or fees. It does not include any adjustment where the patient has purchased a pre-payment certificate (before 2007).

Chart 3 shows the percentage of prescription items prescribed generically (a).

Chart 3: Items prescribed generically (%), 2000-01 onwards

The percentage of items prescribed generically has risen from 66.7% in 2000-01 to more than 80% each year from 2006-07 onwards.

Note: % prescribed generically

Source: NHS Wales Shared Services Partnership

(a) see the notes section at the end of the release for the definition of ‘prescribed generically’
Therapeutic classes – 2016-17

Chart 4 shows the proportion of items prescribed in Wales, while Chart 5 shows the net ingredient cost (NIC) of prescription items in Wales, by the six largest therapeutic classes (by items) during 2016-17. A list of the therapeutic classes is included in the notes section of this release.

- Almost half of all prescription items prescribed in Wales were for the treatment of conditions of the cardiovascular and central nervous systems.
- Almost a third (29% or 23.6 million) of prescription items prescribed were for treatment of the cardiovascular system; this equates to 7.4 items per head of population registered with a GP.
- 20% (16.1 million) items were prescribed for the treatment of the central nervous system, equal to 5.0 items per head of population registered with a GP.
- Although the number of items prescribed for treatment of the central nervous and cardiovascular systems accounted for half of the total items prescribed (see Chart 4), the NIC for the same classes only accounted for 31% of the total (see Chart 5).

Chart 4: Items by therapeutic class, 2016-17

<table>
<thead>
<tr>
<th>Therapeutic Class</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardio-vascular</td>
<td>29%</td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>20%</td>
</tr>
<tr>
<td>Endocrine System</td>
<td>10%</td>
</tr>
<tr>
<td>Gastro-intestinal System</td>
<td>9%</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>7%</td>
</tr>
<tr>
<td>Nutrition And Blood</td>
<td>5%</td>
</tr>
<tr>
<td>Other (a)</td>
<td>20%</td>
</tr>
</tbody>
</table>

Source: NHS Wales shared Services Partnership

(a) ‘Other’ includes: skin, infections, musculoskeletal & joint, obstetrics, gynaecology & urinary tract, malignant disease & immunosuppression, ear, nose & oropharynx, eye, immunological products & vaccines, anaesthesia, other drugs & preparations, dressings, appliances, preparations used in diagnosis, incontinence appliances and stoma appliances.

It should be noted that the NIC in several classes included in ‘other’ (eg stoma appliances) is higher than the NIC of some of the classes shown; the same classes, based on highest number of items prescribed, are shown in both charts.
Chart 6 shows the net ingredient cost (NIC) per item, of prescriptions dispensed in Wales during 2016-17, by therapeutic class.

- The net ingredient cost per item ranged from £2.68 in the cardiovascular system class to £67.03 for items in the stoma appliances class.
- For all therapeutic classes together, the net ingredient cost per item was £7.21, 29p lower than the previous year.

**Chart 6: Net ingredient cost per item, by therapeutic class 2016-17**

---

Note: Only 1 item prescribed in the ‘preparations used in diagnosis’ class in 2016-17, so excluded from this chart. (a) See the notes for a list of therapeutic classes.
Therapeutic classes - 10 year trend

Charts 7-9 show the number of items prescribed, the costs¹ per head of population and the cost per prescription item, by the top ten therapeutic classes, in Wales in 2016-17 compared with 2006-07.

These three charts should be read in conjunction with each other, for while the total net ingredient cost has decreased by just over £2 million (0.4%) compared with 2006-07, 21 million more items were prescribed, an increase of 35%.

¹ Net ingredient cost – see notes section at the end of the release

Items:

- 23.6 million items were prescribed to treat conditions or diseases of the cardiovascular system in Wales in 2016-17, an increase of 21% from the 19.5 million items dispensed in 2006-07.
- Items to treat conditions or diseases of the cardiovascular system accounted for 29% of all items prescribed in 2016-17, down from 33% in 2006-07.
- 16.1 million items were prescribed to treat conditions or diseases of the central nervous system in Wales in 2016-17, an increase of 48% from the 10.9 million items dispensed in 2006-07.
- Of the ten largest groups, the biggest increase over the 10 years is in the nutrition and blood class, with 3.6 million items prescribed in 2016-17 compared with 2.1 million in 2006-07.
- Over the last 10 years, the number of items prescribed in all classes has increased by 35%, up from 59.1 million items in 2006-07 to 80.0 million in 2016-17.

Chart 7: Prescription items by top ten therapeutic classes in 2016-17 compared with 2006-07

Source: NHS Wales Shared Services Partnership

See StatsWales for more detail
Net ingredient cost (NIC):

- The total net ingredient cost of items prescribed in the largest class (by cost), the central nervous system, was £116.8 million in 2016-17, an increase of 2% from the £114.8 million in 2006-07.

- The total net ingredient cost of items prescribed in the second largest class (by cost), the endocrine system, which overtook respiratory as the second largest class (by cost) in 2015-16, was £89.0 million in 2016-17, up 51% from £59.1 million in 2006-07.

- The biggest increase in cost over the 10 years is in the appliances class, up 116% in 2016-17 (£18.3 million) compared with 2006-07 (£8.5 million).

- The total net ingredient cost of items in the cardiovascular system class has fallen by 52% over the last 10 years, from £130.7 million in 2006-07 to £63.1 million in 2016-17¹.

- The total net ingredient cost of items in the gastro-intestinal system class has fallen by 21% over the last 10 years, from £37.5 million to £29.6 million.

- Over the last 10 years, the total net ingredient cost for all classes has decreased by 0.4%, down from £578.8 million in 2006-07 to £576.7 million in 2016-17.

- A major change in the last 10 years has been the fact that the cardiovascular system was the largest class by cost 10 years ago, but since 2007-08 the central nervous system has taken over as the largest group by cost.

¹ The NICs of a number of medicines in the cardiovascular class have decreased considerably in recent years. The decrease is related to changes in the price the NHS pays for a medicine when the relevant originator brand loses its patent protection and equivalent generic products, which generally have a lower acquisition cost, become available.

Chart 8: Net ingredient cost by top ten therapeutic classes in 2016-17 compared with 2006-07

Source: NHS Wales Shared Services Partnership

See StatsWales for more detail
Net ingredient cost (NIC) per prescription item:

- In 2016-17 the most expensive therapeutic class, in terms of cost per item, (but excluding ‘preparations used in diagnosis’ where only 1 prescription item was prescribed), was stoma appliances, at £67.03 per prescription item, about the same as in 2006-07 (£65.05).

- The cost per item has fallen significantly in the 2 biggest classes by number of items prescribed; cardiovascular by 60%, from £6.69 in 2006-07 to £2.68 in 2016-17, and central nervous system by 31%, from £10.51 to £7.24.

- While many of the classes show a reduction in cost per item from 2006-07 to 2016-17, a few have risen, in particular anaesthesia, up 85% £10.79 to £20.06.

Chart 9: Net ingredient cost per prescription item by top ten therapeutic classes in 2016-17 compared with 2006-07

Source: NHS Wales Shared Services Partnership

‘Preparations used in diagnosis’ have been excluded from this analysis as in most years very few or no items were prescribed.

See StatsWales for more detail.
Chart 10 shows the annual percentage change, over the last 10 years, of the total number of prescription items prescribed and the total net ingredient cost.

- Apart from 2012-13 when the net ingredient cost fell by 5.1%, the annual percentage change has fluctuated around zero, but it fell again in 2016-17 - by 2.8%.
- The annual percentage increase in the number of items has fallen slightly from around 5% a year to 1% in each of the last 2 years.

Chart 10: Items and net ingredient cost, annual percentage change, 2006-07 to 2016-17

Charts 11a to 11c shows the annual percentage change, over the last 10 years, of the number of items prescribed in the three largest classes, cardiovascular system, central nervous system, and endocrine system, plus all items.

Charts 11a to c: Annual percentage change of the number of items dispensed in the three largest classes (cardiovascular, central nervous and endocrine systems)
Analysis by Local Health Board

The following charts show the numbers of items prescribed by GPs contracted to Welsh Health Boards together with the associated NIC. Rather than comparing items per head of population registered with a GP, the charts show items and NIC per Prescribing Unit. Prescribing units (PUs) are calculated by giving a greater weight (by a factor of three) to the registered population aged 65 or over. They have been adopted here to take account of the greater need of elderly patients for medication and so to make more meaningful comparisons between Health Boards. The remaining differentials may be related to relative need and local culture and practice.

25% of the population registered with a GP in Powys was aged 65 or over in 2016 whereas only 15% of Cardiff & Vale's population fell into this group. Cwm Taf, Abertawe Bro Morgannwg and Aneurin Bevan also had relatively fewer older GP patients (less than 20% of the total population) and Hywel Dda had the ‘oldest’ population after Powys.

Chart 12 shows the number of items prescribed per prescribing unit – see above - by Local Health Board, in 2016-17.

The number of items prescribed per prescribing unit in 2016-17 was 17.9 for Wales, and varied across the LHBs from 15.2 in Cardiff & Vale to 20.5 in Cwm Taf.

Chart 12: Number of prescription items per prescribing unit, by Local Health Board, 2016-17

Sources: NHS Wales Shared Services Partnership and GMS
¹Abertawe Bro Morgannwg

Chart 13 shows the net ingredient cost - see note (a) - of items prescribed by GPs in Wales, per prescribing unit, by LHB, in 2016-17.

The net ingredient cost per prescribing unit in 2016-17 was £128.92 in Wales, and ranged from £122.07 in Cardiff & Vale to £143.51 in Cwm Taf.

GPs in Cardiff & Vale prescribed fewer items per prescribing unit than in other Health Boards but at a higher cost per item: £8.27 per item as compared to Cwm Taf, for example, which had the highest rates per prescribing unit for both items and cost but a lower cost per item (£7.01).

Chart 13: Net ingredient cost per prescribing unit, by Local Health Board, 2016-17

Sources: NHS Wales Shared Services Partnership and GMS census
¹Abertawe Bro Morgannwg

(a) Refers to the cost (which the dispenser is reimbursed) of the drug before discounts and does not include any dispensing costs or fees.
Charts 14a-d look at the number of items prescribed per prescribing unit by Local Health Board, in 2016-17 for the top 5 classes (by number of items prescribed) – cardiovascular, central nervous, endocrine, gastro-intestinal and respiratory system.

Cwm Taf has the highest prescribing rates for each of the classes shown below. The lowest rates were seen in Cardiff & Vale for the following classes: cardiovascular, endocrine and gastro-intestinal. Powys had the lowest rates for the central nervous system and respiratory classes, once the rates are weighted to allow for the relatively older population.

**Chart 14a: Number of items per prescribing unit, cardiovascular system, 2016-17**

In Wales, the number of items prescribed - per prescribing unit – in the cardiovascular system class was 5.3. Across the LHBs, this ranged from 4.1 in Cardiff & Vale to 6.3 in Cwm Taf.

**Chart 14b: Number of items per prescribing unit, central nervous system, 2016-17**

The number of items prescribed - per prescribing unit – in the central nervous system class was 3.6 for Wales as a whole. Across the LHBs, this ranged from 2.9 in Powys to 4.2 in Cwm Taf.

Note that the scale on the two charts on this page is not the same as the scale on Charts 14c, 14d and 14e on the following page.
In Wales, the number of items prescribed - per prescribing unit – in the endocrine system class was 1.7.

Across the LHBs, this varied from 1.4 in Cardiff & Vale to 1.9 in Cwm Taf.

Prescribing units

The number of items prescribed - per prescribing unit – in the gastro-intestinal system class across Wales was 1.6.

Within the LHBs, this ranged from 1.4 in Cardiff & Vale to 1.9 in Cwm Taf.

Prescribing units

In Wales, the number of items prescribed - per prescribing unit – in the respiratory system class was 1.3.

Across the LHBs, this ranged from 1.1 in Cardiff & Vale to 1.7 in Cwm Taf.

Prescribing units

Note that the scale on the three charts on this page is not the same as the scale on Charts 14a and 14b on the previous page.
Key quality information

Quality report
We publish a detailed quality report on ‘Prescriptions by GPs in Wales’ statistics. The quality report includes information on definitions and coverage, and details of our users.

Source
The data are obtained from Prescribing Services, NHS Wales Shared Services Partnership and are based on information obtained from prescriptions sent to Prescribing Services for payment.

Further data is available on the Prescribing Services website; from April 2013, prescribing data by individual GP practices is also available via the Prescribing Services website.

Coverage
This release covers prescription items prescribed (and dispensed) or dispensed by GPs in Wales. Excluded from this release are prescriptions which were prescribed but, for a variety of reasons, have not been dispensed. It also covers prescriptions submitted by prescribing doctors for items personally administered. Detailed data on all items dispensed in the community in Wales (including items not prescribed by GPs) are published in a separate Statistical Release together with comparisons of prescribing patterns in the four UK countries.

The statistics are based on the data provided by Prescribing Services following their payment processing. Prescribing Services, NHS Wales Shared Services Partnership have stated that due to the complex and manual processes involved there may be inaccuracies in capturing prescription information which are then reflected in the data. Internal quality assurance processes exist and currently the prescription processing activity is internally audited at around 99% accuracy (i.e. at least 99% of prescriptions are processed accurately).

Definitions

Items dispensed
A prescription item refers to a single item prescribed by a doctor on a prescription form. If a prescription form includes three items it is counted as three prescription items. A prescription item may be for a variable quantity eg 14, 28 or 56 tablets. A prescription item consists of a quantity of tablets or other preparation. This means that the cost per item does not equate to the cost, for example, per tablet or per pack of tablets but to the average number of packs prescribed per item.

Net Ingredient Cost (NIC)
NIC refers to the cost of the drug before discounts and does not include any dispensing costs or fees. It does not include any adjustment where the patient has purchased a pre-payment certificate.

Figures quoted for net ingredient cost for all years are unadjusted for inflation. Standard adjustments for inflation are not considered appropriate as drug prices are subject to controls under the Pharmaceutical Price Regulation Scheme and to other central controls.
Free prescriptions
Prescription charges were frozen on 1 April 2001 and gradually reduced each year until free prescriptions were introduced in Wales on 1 April 2007. Before 2007 prescriptions were free for those people under 25 or over 60, or who had certain medical conditions.

Generic prescribing
A prescription item prescribed generically refers to a prescription which has been written using the British Approved Name (BAN), International Non-proprietary Name (INN) or the scientific name of the active ingredient rather than the proprietary name.

Registered population
This is the number of people registered with a GP in Wales. In 2009 this was at 1 October, otherwise this is at 30 September. The source is the annual GP Census.

Prescribing units (PUs)
PUs are calculated by giving a greater weight (by a factor of three) to the population aged 65 or over (used as the denominator). They have been adopted here to take account of the greater need of elderly patients for medication and so to make more meaningful comparisons between Health Boards.

As an example for 2014-15:

Total prescription items: 78,512,726
Total population age 0-64, 2014 population registered with a GP: 2,555,500
Total population aged 65 or over: 617,494
PUs: 4,407,982 (2,555,500+(3 * 617,494))
Items per PU: 17.81

BNF
The British National Formulary (BNF) is a joint publication of the British Medical Association and the Royal Pharmaceutical Society. It is published biannually under the authority of a Joint Formulary Committee which comprises representatives of the two professional bodies and of the UK Health Departments.

Therapeutic classification
PCA data are based on the therapeutic grouping used in the British National Formulary. The classification in this report is based on the September 2016 BNF.

NHS Prescription Services have created pseudo-BNF chapters, for items that cannot be found in BNF chapters 1 to 15. The majority of these items are dressings and appliances, which NHS Prescription Services have classified into four pseudo-BNF chapters (20 to 23). However some gel and colloid dressings that are classified as drugs are included in a pseudo section within BNF 13 (13.13). NHS Prescription Services have produced a booklet on BNF classifications and the pseudo classifications used.
Examples of the conditions covered by each group (unless group is self-explanatory) are given below:

- **Gastro-intestinal system**: including preparations for the management of indigestion, diarrhoea, constipation, haemorrhoids, ulcerative colitis and Crohn’s disease
- **Cardiovascular system**: including preparations for the management of arrhythmia (irregular heart rhythm), hypertension (high blood pressure), heart failure and high cholesterol
- **Respiratory system**: including preparations for the management of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergies, cough and congestion
- **Central nervous system**: including preparations for the management of anxiety, sleeplessness, depression, pain, epilepsy, substance misuse, Parkinson’s disease and Alzheimer’s disease
- **Infections**: including preparations for the treatment of infection
- **Endocrine system**: including preparations for the management of diabetes, an under or over active thyroid gland and other hormonal conditions
- **Obstetrics, gynaecology and urinary tract disorders**: including contraceptives and preparations used in obstetrics
- **Malignant disease and immunosuppression**: including preparations for the treatment and management of cancer and conditions affecting the immune system
- **Nutrition and blood**: vitamins, minerals and prescribed foods
- **Musculoskeletal and joint disorders**: including preparations for the management of rheumatoid arthritis and gout, myasthenia gravis, spasticity and topical treatments for pain
- **Eye**: including preparations for the treatment and management of eye infections and glaucoma
- **Ear, nose and oropharynx**: including preparations for the treatment and management of conditions affecting the ear, nose and throat
- **Skin**: including preparations for the treatment and management of eczema, psoriasis, acne, warts and verrucae
- **Immunological products and vaccines**: including preparations for the treatment of anaemia, vitamin preparations and supplements
- **Anaesthesia
- Preparations used in diagnosis
- Other drugs and preparations
- Dressings
- Appliances
- Incontinence supplies
- Stoma appliances
A full list of the therapeutic classes (BNF chapters) and their sub groups are shown in the following table.

**Therapeutic class**

<table>
<thead>
<tr>
<th>Gastro-intestinal System</th>
<th>Malignant Disease and Immunosuppression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antacids</td>
<td>Cytoxic drugs</td>
</tr>
<tr>
<td>Antispasmodic and other drugs altering gut motility</td>
<td>Drugs affecting the immune response</td>
</tr>
<tr>
<td>Ulcer healing drugs</td>
<td>Sex hormones and hormone antagonists in malignant disease</td>
</tr>
<tr>
<td>Antidiarrhoeal drugs</td>
<td></td>
</tr>
<tr>
<td>Treatment of chronic diarrhoeas</td>
<td></td>
</tr>
<tr>
<td>Laxatives</td>
<td></td>
</tr>
<tr>
<td>Preparations for haemorrhoids</td>
<td></td>
</tr>
<tr>
<td>Stoma care</td>
<td></td>
</tr>
<tr>
<td>Drugs affecting intestinal secretions</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiovascular System</th>
<th>Nutritional and Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive inotropic drugs</td>
<td>Anaemias and other blood disorders</td>
</tr>
<tr>
<td>Diuretics</td>
<td>Fluids and electrolytes</td>
</tr>
<tr>
<td>Anti-arrhythmic drugs</td>
<td>Oral nutrition</td>
</tr>
<tr>
<td>Beta-adrenoceptor blocking drugs</td>
<td>Minerals</td>
</tr>
<tr>
<td>Antihypertensive therapy</td>
<td>Vitamins</td>
</tr>
<tr>
<td>Nitrates and other vasodilators, and calcium channel blockers</td>
<td>Bitters and tonics</td>
</tr>
<tr>
<td>Sympathomimetics</td>
<td>Metabolic disorders</td>
</tr>
<tr>
<td>Anticoagulants and protamine</td>
<td>Compound vitamin / mineral formulations</td>
</tr>
<tr>
<td>Antiplatelet drugs</td>
<td>Health supplements</td>
</tr>
<tr>
<td>Antifibrinolytic drugs and haemostatics</td>
<td>Other health supplements</td>
</tr>
<tr>
<td>Lipid-lowering drugs</td>
<td></td>
</tr>
<tr>
<td>Local sclerosants</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Respiratory System</th>
<th>Eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilators</td>
<td>Anti-infective eye preparations</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Corticosteroids and other anti-inflammatory preparations</td>
</tr>
<tr>
<td>Cromoglycate and related therapy</td>
<td>Mydriatics and cycloplegics</td>
</tr>
<tr>
<td>Allergic disorders</td>
<td>Treatment of glaucoma</td>
</tr>
<tr>
<td>Oxygen</td>
<td>Local anaesthetics</td>
</tr>
<tr>
<td>Mucolytics</td>
<td>Miscellaneous ophthalmic preparations</td>
</tr>
<tr>
<td>Aromatic inhalations</td>
<td>Contact lenses</td>
</tr>
<tr>
<td>Cough preparations</td>
<td></td>
</tr>
<tr>
<td>Systemic nasal decongestants</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Central Nervous System</th>
<th>Skin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypnotics and anxiolytics</td>
<td>Vehicles and emulsifying agents</td>
</tr>
<tr>
<td>drugs used in psychoses and related disorders</td>
<td>Emollient and barrier preparations</td>
</tr>
<tr>
<td>Antidepressant drugs</td>
<td>Local anaesthetics and antipruritics</td>
</tr>
<tr>
<td>Central nervous system stimulants</td>
<td>Topical corticosteroids</td>
</tr>
<tr>
<td>Appetite suppressants</td>
<td>Preparations for eczema and psoriasis</td>
</tr>
<tr>
<td>Drugs used in nausea and vertigo</td>
<td>Preparations for acne</td>
</tr>
<tr>
<td>Analgesics</td>
<td>Preparations for warts and calluses</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td>Sunscreens and camouflagers</td>
</tr>
<tr>
<td>Drugs used in parkinsonism and related disorders</td>
<td>Shampoos and some other scalp preparations</td>
</tr>
<tr>
<td>Drugs used in substance dependence</td>
<td>Anti-infective skin preparations</td>
</tr>
<tr>
<td>Drugs used in Alzheimer's disease</td>
<td>Disinfectants and cleansers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Infections</th>
<th>Skin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibacterial drugs</td>
<td>Antiperspirants</td>
</tr>
<tr>
<td>Antifungal drugs</td>
<td>Wound management products</td>
</tr>
<tr>
<td>Antiviral drugs</td>
<td>Miscellaneous topical preparations</td>
</tr>
<tr>
<td>Antiprotozoal drugs</td>
<td>Immunological Products and Vaccines</td>
</tr>
<tr>
<td>Anthelminitics</td>
<td>Vaccines and antisera</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endocrine System</th>
<th>Immunoglobulins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs used in diabetes</td>
<td>Anaesthesia</td>
</tr>
<tr>
<td>Thyroid and antithyroid drugs</td>
<td>General anaesthesia</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Local anaesthesia</td>
</tr>
<tr>
<td>Sex hormones</td>
<td>Preparations used in Diagnosis</td>
</tr>
<tr>
<td>Hypothalamic and pituitary hormones and antioestrogens</td>
<td>X-ray contrast media</td>
</tr>
<tr>
<td>Other endocrine drugs</td>
<td>Other Drugs and Preparations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Obstetrics, Gynaecology and Urinary Tract Disorders</th>
<th>Appliances</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs used in obstetrics</td>
<td>Incontinence Supplies</td>
</tr>
<tr>
<td>Treatment of vaginal and vulval conditions</td>
<td>Stoma Appliances</td>
</tr>
<tr>
<td>Contraceptives</td>
<td></td>
</tr>
<tr>
<td>Drugs used for genito-urinary disorders</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** some preparations have multiple indications and may therefore be classified under more than one therapeutic class.
Notes

Pharmacy and appliance contractor dispensing data
Data on Pharmacy and Appliance Contractor Dispensing Data in Wales is available from NHS Wales Shared Services Partnership, Primary Care Services.

Data for other UK countries
Prescribing patterns for the four UK countries are presented in the annual ‘Prescriptions dispensed in the community’ statistical release. Data for other UK countries can be accessed via the following webpages:

England

Prescriptions dispensed in the community

Prescription Cost Analysis (PCA)

Scotland

Prescription Cost Analysis (PCA)
Prescription Cost Analysis - Scotland

Northern Ireland

Prescription Cost Analysis (PCA)
Prescription Cost Analysis - Northern Ireland

Note that varying prescribing practice may affect the interpretation of UK country comparisons.

The figures supplied in this release cover items dispensed in Wales.

Users and uses of these statistics
We believe the key users of prescription statistics are:

- Ministers and the Members Research Service in the National Assembly for Wales;
- policy makers of the Welsh Government;
- other government departments;
- National Health Service and Public Health Wales;
- students, academics and universities;
- General Medical Council and other professional organisations; and
- individual citizens and private companies.

The statistics are used in a variety of ways. Some examples of the uses include:

- advice to Ministers; and.
- to inform debate in the National Assembly for Wales and beyond.
**National Statistics status**

The United Kingdom Statistics Authority has designated these statistics as National Statistics, in accordance with the Statistics and Registration Service Act 2007 and signifying compliance with the Code of Practice for Official Statistics.

National Statistics status means that official statistics meet the highest standards of trustworthiness, quality and public value.

All official statistics should comply with all aspects of the Code of Practice for Official Statistics. They are awarded National Statistics status following an assessment by the UK Statistics Authority’s regulatory arm. The Authority considers whether the statistics meet the highest standards of Code compliance, including the value they add to public decisions and debate.

It is Welsh Government’s responsibility to maintain compliance with the standards expected of National Statistics. If we become concerned about whether these statistics are still meeting the appropriate standards, we will discuss any concerns with the Authority promptly. National Statistics status can be removed at any point when the highest standards are not maintained, and reinstated when standards are restored.

Our statistics take into account our disclosure control guidance and follow ONS confidentiality guidelines for Health statistics available from [ONS best-practice guidelines](#).

**Well-being of Future Generations Act**

The Well-being of Future Generations Act 2015 is about improving the social, economic, environmental and cultural well-being of Wales. The Act puts in place seven well-being goals for Wales. These are for a more equal, prosperous, resilient, healthier and globally responsible Wales, with cohesive communities and a vibrant culture and thriving Welsh language. Under section (10)(1) of the Act, the Welsh Ministers must (a) publish indicators (“national indicators”) that must be applied for the purpose of measuring progress towards the achievement of the Well-being goals, and (b) lay a copy of the national indicators before the National Assembly. The 46 national indicators were laid in March 2016.

Information on indicators and associated technical information - [How do you measure a nation’s progress?](#) - [National Indicators](#)

Further information on the [Well-being of Future Generations (Wales) Act 2015](#)

The statistics included in this release could also provide supporting narrative to the national indicators and be used by public services boards in relation to their local well-being assessments and local well-being plans.
Further details

This release is available at: http://gov.wales/statistics-and-research/prescriptions-general-medical-practitioners/?lang=en

Further information on methods and quality can be found in the Quality Report.

Next update

The next release covering 2017-18 will be published in September 2018.

We want your feedback

We welcome any feedback on any aspect of these statistics, which can be provided by email to stats.healthinfo@gov.wales

Open Government Licence

All content is available under the Open Government Licence v3.0, except where otherwise stated.